|Progression of IgA Nephropathy under Current Therapy Regimen in a Chinese Population|
|Li, Xiangling1,2,3,4,5; Liu, Youxia1,2,3,4; Lv, Jicheng1,2,3,4; Shi, Sufang1,2,3,4; Liu, Lijun1,2,3,4; Chen, Yuqing1,2,3,4; Zhang, Hong1,2,3,4|
|刊名||CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY|
|WOS标题词||Science & Technology|
|类目[WOS]||Urology & Nephrology|
|研究领域[WOS]||Urology & Nephrology|
|关键词[WOS]||IMMUNOGLOBULIN-A NEPHROPATHY ; RANDOMIZED CONTROLLED-TRIAL ; GALACTOSE-DEFICIENT IGA1 ; RISK-FACTORS ; DISEASE PROGRESSION ; ALPHA-TOCOPHEROL ; ORAL CALCITRIOL ; RENAL SURVIVAL ; PROTEINURIA ; GLOMERULONEPHRITIS|
Background and objectives
Current therapy for IgA nephropathy mainly includes renin-angiotensin system inhibitors and adding steroids for patients with persistent proteinuria. This study aimed to evaluate kidney disease progression and its risk factors in a Chinese cohort under current therapy.
Design, setting, participants, & measurements
Patients with IgA nephropathy followed up for at least 12 months from a prospective database were involved. Renal survival and the relationship between clinical parameters and composite kidney failure events (defined as end stage kidney failure or eGFR halving) were assessed.
Overall, 703 patients between 2003 and 2011 were enrolled in this study, with a mean follow-up time of 45 months. Mean eGFR was 84.0 ml/min per 1.73 m(2), systolic BP was 124 mmHg, and time-averaged mean arterial pressure was 90.0 mmHg. Median proteinuria at baseline was 1.60 g/d, and time-averaged proteinuria was 0.80 g/d. The mean rate of eGFR decline was -3.12 ml/min per 1.73 m(2) per year (95% confidence interval, -19.07 to 11.80), and annual end stage kidney failure rate was 2.3%. Multivariate Cox regression analyses revealed that baseline eGFR (hazard ratio, 0.76 per 10 ml/min per 1.73 m(2); 95% confidence interval, 0.66 to 0.91), proteinuria at 6 months (hazard ratio, 1.53 per g/d; 95% confidence interval, 1.27 to 1.84), and systolic BP control at 6 months (hazard ratio, 1.36 per 10 mmHg; 95% confidence interval, 1.05 to 1.77) were associated with composite kidney failure events. Baseline eGFR (regression coefficient, -0.06; 95% confidence interval, -0.07 to -0.04), time-averaged proteinuria (regression coefficient, -0.21; 95% confidence interval, -0.25 to -0.16), and time-averaged mean arterial pressure (regression coefficient, -0.15; 95% confidence interval, -0.21 to -0.09) were independent predictors of the slope of eGFR by linear regression.
Lower proteinuria and lower BP were associated with slower eGFR decline and lower risk of end stage kidney failure in patients currently being treated for IgA nephropathy.
|项目编号||81322009 ; 81270795 ; 2012CB517700 ; NCET-12-0011 ; Z12110700100000 (2011-4021-06) ; 81021004|
|资助机构||National Natural Science Foundation (NSF) of China ; Major State Basic Research Development Program of China 973 Program ; Program for New Century Excellent Talents in University from the Ministry of Education of China ; Capital Clinical Research Grant ; NSF for Innovative Research Groups of China|
|作者单位||1.Minist Hlth China, Key Lab Renal Dis, Beijing, Peoples R China|
2.Peking Univ, Inst Nephrol, Beijing 100871, Peoples R China
3.Peking Univ, Div Renal, Hosp 1, Beijing 100871, Peoples R China
4.Peking Univ, Minist Educ, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing 100871, Peoples R China
5.Weifang Med Coll, Affiliated Hosp, Dept Nephrol, Weifang, Shandong, Peoples R China
|Li, Xiangling,Liu, Youxia,Lv, Jicheng,et al. Progression of IgA Nephropathy under Current Therapy Regimen in a Chinese Population[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,2014,9(3):484-489.|
|APA||Li, Xiangling.,Liu, Youxia.,Lv, Jicheng.,Shi, Sufang.,Liu, Lijun.,...&Zhang, Hong.(2014).Progression of IgA Nephropathy under Current Therapy Regimen in a Chinese Population.CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY,9(3),484-489.|
|MLA||Li, Xiangling,et al."Progression of IgA Nephropathy under Current Therapy Regimen in a Chinese Population".CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 9.3(2014):484-489.|